Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients.
Abstract
Since the introduction of replacement therapy in the early 1960s by the infusion of plasmaderived factor VIII and IX preparations important changes have occurred for hemophilia patients. We studied the medical and social developments over thirty years of hemophilia treatment. Our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in a decrease in bleeding frequency and an improvement of the medical and social circumstances of patients.
Introduction
Hemophilia is a X-linked genetic bleeding disorder caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Severe forms are characterized by major bleeding after minor trauma. These hemorrhages often occur into joints eventually causing arthropathy, which is associated with physical and psychosocial impairment 1 .
Since the introduction of replacement therapy in the early 1960s, the infusion of plasmaderived factor VIII and IX preparations, important changes have occurred for hemophilia patients 2, 3 . For patients with hemophilia mean life expectancy has increased over the years from lower than 30 years in 1960 to an almost normal life expectancy of 68 years in 1992 4, 5 . Prophylaxis was introduced in the Netherlands in the late 1960s 6, 7 . As from the 1970s it became possible for patients to treat themselves at home and the introduction of clotting factor concentrates in 1978 further facilitated developments. Although the general superiority of prophylactic treatment over on-demand treatment has been demonstrated [8] [9] [10] , the question on when and in whom to start and how to dose prophylactic therapy remains a subject of discussion 11 . Some believe that intensified on-demand treatment may be as effective as prophylaxis. Arguments in favor of on-demand therapy include fewer exposures with a potential concommitant reduction in pathogen exposure, less financial burden for the family (depending on the health care system) and society and greater therapeutic maneuverability in times of reduced product availability 12 . Randomized clinical trials to compare cost-effectiveness of prophylaxis and on demand treatment are ongoing 13, 14 .
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Although treatment with clotting factor concentrate has enabled patients to participate fully in normal life, the infusion of plasma products also has had important adverse effects, such as infections with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and inhibitor development. Of the Dutch hemophilia patients who were treated with plasmaderived clotting factors before 1985 17% became infected with the human immunodeficiency virus (HIV) 2 . Since 1985 plasma-derived products are safe for hepatitis B and HIV and since 1992 also for HCV 15 .
In 1995 recombinant FVIII products have been introduced in the Netherlands and have become increasingly used 16 , especially in previously untreated patients; along with the use of purified plasma-derived products this minimizes the risk of transmission of HIV or HCV 17 . Today, the most important complication of clotting factor treatment is the development of neutralizing antibodies (inhibitors) against factor VIII or IX 18 .
Objective
In the Netherlands a series of five national postal surveys 19, 20 have been performed, from 1972 onward. In this study we evaluated the most important medical and social developments over the last three decades of hemophilia treatment. 
Data analyses
All analyses were stratified by the severity of hemophilia, and often by age category as well. As the clinical characteristics of hemophilia A and hemophilia B do not differ for both types we present combined results for hemophilia A and B. Data on the treatment modality, the number of bleeding episodes, the use of hospital facilities, and absence from school or work referred to the year that preceded the questionnaire surveys (2000).
Children were defined as patients younger than 16, adolescents as patients between 16 and 25 and adults as patients aged above 25 years. The use of prophylaxis refers to patients who received prophylaxis as their main treatment modality, excluding patients who received a combination of on demand treatment and prophylaxis during risk periods.
Absence from school was calculated only for that part of the population that followed a full-time education. Absence from work was calculated for patients aged 16 to 65 who had a paid job (full-time or part-time). The inactivity ratio was calculated as the ratio of inactivity in the study population and inactivity in Dutch men. Patients that did not have a full-time or part-time paid job were defined as inactive. Descriptive statistics for age, the use of hospital facilities, absence from work and employment were compared to national figures for the general male population that were provided by the Central Bureau of Statistics Netherlands (http://www.cbs.nl/nl/cijfers/statline/index.htm). Self reported measures on joint impairment were obtained for a series of 16 joints which are, the neck, the left and right shoulder, the back, the left and right elbow, the left and right wrist, the left and right hand and fingers, the left and right hip, the left and right knee and the left and right ankle. The possible scores were 0 (no impairment), 1 (some impairment without daily problems), 2 (some impairment with daily problems), and a maximum of 3 (severe impairment with complete loss of function). of patients the genetic inheritance pattern of the disease was that of isolated hemophilia; they had no other family members with hemophilia. This proportion had remained constant over the 30 years spanned by the surveys. Of patients with severe hemophilia 38% were isolated patients, in patients with moderate this was 13%.
Treatment
In 2001, 580 patients (54%) received treatment on-demand, and 305 patients (29%)
prophylaxis, while 127 patients (12%) at times were treated on-demand and at other times prophylactically. For 54 patients (5%) no data were available about treatment, and most of these (n=45) had mild hemophilia. Prophylactic treatment was used mostly in children and adolescents with severe hemophilia (Table 2 ). This group also showed the largest increase Patients who had been treated in the year preceding the survey had equally often used plasma-derived products (41%, n=300) and recombinant factor VIII or IX products (48%, n=349). Among children below the age of 16, a larger proportion solely used a recombinant product (78%, n=155). Table 3 hospitalization, which occurred in 26% (n=107) of patients with severe hemophilia, in 17% of patients with moderate hemophilia and in 13% of patients with mild hemophilia in a five-year period preceding the survey. In patients with mild hemophilia 50% of orthopedic surgery was related to hemophilia, for patients with moderate and severe hemophilia this was 76% and 92%, respectively.
Outcome of treatment
In 2001, absence from school was seven days (range 0-90) among the 121 patients (29%) with severe hemophilia who participated in full time education, of which four days were due to hemophilia. In patients with moderate hemophilia this was five days, of which two days were due to hemophilia. The median number of days that patients with mild hemophilia were absent from school was three days (range 0-40), of which one day was due to hemophilia. Absence from work, for 157 patients with a paid job (full-time or parttime) in 2001, was on average five days, ranging from 0 days to a full year. Restricting to patients working full-time the median number of days absent from work was three (range 0-242, mean=10.7 days). Considering a total work year of 260 days, absence from work was 4.1%. In the Dutch population this ranges from 5.5% (private companies) to 7.7% (civil service). In patients with moderate hemophilia this was three days (range 0-365).
Restriction on the capacity to perform regular labor among patients between 15 and 64 years with severe and moderate hemophilia is shown in Table 4 . Of the 'inactive' patients 69 patients 75% were officially registered as fully or partially disabled. Although the percentage of 'inactive' patients decreased compared to earlier surveys, the inactivity ratio 
Joints
Severe joint impairment was most frequently reported for the ankle joints, the knee and the elbow joints by patients with severe and moderate hemophilia ( Table 5) (Table 6c ). The absence of joint impairment was related to age; it was reported by 59% of patients aged 0-16, 17% of those aged between 17 and 25 years, and three percent of patients with severe hemophilia over 40 years old. In three decades the percentage of patients that reported no joint damage in the age categories 0 to16 years increased from 40% to 59%, and in the age category 17 to 25 years from 5% to 17%.
Side effects of treatment
The presence of neutralizing antibodies to factor VIII or IX (inhibitors), either in the present or in the past, was reported by 13% (52/420) of patients with severe hemophilia (14% (51/388) in 1992), by 7% of patients with moderate hemophilia and by 5% of patients with mild hemophilia (Table 7) . Of these patients 86 (96%) had hemophilia A. 
13
In 2001, 29 patients (5%) treated before 1985 were HIV positive, of which twenty-five patients were also infected with HCV. In 1992 55 (8%) patients were HIV positive. In 2001 333 patients (44%) reported a current infection with hepatitis C, whereas 97 patients (13%) had been infected in the past but have cleared the virus naturally or through treatment. As no specific items regarding this subject were included in the questionnaire we were not able to make a distinction between these two ways of clearance. hemophilia, and 70% participated in our study. As the non-responders appeared not to differ from the responding patients in severity and type of hemophilia and were only slightly younger (33 vs. 36 years) we feel confident to generalize our findings to the total population of hemophilia patients in the Netherlands.
Self-reported data may be less objective compared to medical records or laboratory data, but offer an important insight in the view of patients of their own situation. Because patients with hemophilia, especially patients with severe hemophilia, are confronted with their disease on a daily basis and are well informed about their disease, we assume data on treatment and side effects of treatment are trustworthy. To rule out error in information on type and severity of hemophilia, we contacted the treating physicians. 1992, which is in line with the findings of a single center study 8 . Although evolution to a more intense treatment regimen has resulted in a decrease of hospitalization, the percentage of patients with hemophilia annually admitted to hospital is still three times increased compared to the Dutch male population. However, the number of days spent in hospital has decreased substantially from 28 to 7 days and is now equal to the mean duration of stay in hospital for all who are admitted. In our population hospital admission occurred frequently in patients with mild and moderate hemophilia, which can be explained by the policy to admit patients with hemophilia for small operations or for observation after falls.
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As we also observed in the 1991 survey, there was no further improvement in perceived joint impairment compared to the earlier surveys covering the period 1972-1985. A previous study presenting joint pathology by radiological assessments showed a clear improvement of the joint scores over the same period 8 . It may well be that perceived joint impairment did not further improve due to different appreciations of signs and symptoms over time. Remarkably, even among patients under age 25 with severe hemophilia, 7%
reported at least one joint with complete loss of function in the latest survey. The discrepancy between radiological assessments and our findings will be subject of future study. Some patients with moderate hemophilia reported severe joint impairment.
Although our measure for joint impairment was self-reported and subjective, we may conclude from this that the goal of prophylactic therapy, which is aimed at a trough level of 1%, may not be ambitious enough.
We observed a cumulative incidence of inhibitors of 13% in patients with severe hemophilia, which is similar to other studies of previously treated patients 24 . in the 1990s 8 . Clotting products have not become cheaper, which implies a larger increase in costs, which, however has been accompanied by direct and indirect gains, e.g., a decrease in absence from work and increased employment rates.
In conclusion our study shows that the treatment of patients with severe hemophilia in the Netherlands has focused on the use of prophylactic treatment, especially in children. This has resulted in an improvement of the medical and social situation of patients. Although the current situation of Dutch hemophilia patients proves to be good, more improvements are possible. A remarkable finding was that the prevalence of perceived joint impairments among young patients did not show the decrease we had expected.
For Table 6b . Self-reported impairment of the joints in patients with moderate hemophilia.
Median joint score over 16 joints (min=0, max=48) and severe joint impairment in the left and right ankle, elbow and knee joints. 
